TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
May 09, 2024 07:00 ET
|
TScan Therapeutics, Inc.
Patient dosed with TSC-203-A0201 targeting cancer-associated antigen PRAME On-track to report initial data from the solid tumor clinical trial in 2024 WALTHAM, Mass., May ...
I risultati di TAR-210 mostrano una sopravvivenza libera da recidiva del 90 per cento e una risposta completa del 90 per cento rispettivamente nei pazienti con tumore della vescica non muscolo-invasivo ad alto rischio e a rischio intermedio
May 09, 2024 06:31 ET
|
Janssen Cilag International NV
I risultati aggiornati consolidano il potenziale di TAR-210 per trasformare il trattamento del tumore della vescica non muscolo-invasivo con alterazioni del recettore del fattore di crescita dei...
Les résultats de l’étude portant sur le TAR-210 indiquent un taux de survie sans récidive de 90 pour cent et 90 pour cent de réponse complète chez les patients atteints d’un cancer de la vessie n’infiltrant pas le muscle à haut risque et à risque intermédiaire, respectivement
May 09, 2024 06:14 ET
|
Janssen Cilag International NV
Les résultats actualisés renforcent le potentiel du TAR-210 pour transformer le traitement du cancer de la vessie n’infiltrant pas le muscle et présentant des altérations du récepteur du facteur de...
Los resultados obtenidos con TAR-210 muestran una supervivencia libre de recidiva del 90 por ciento y una respuesta completa del 90 por ciento en pacientes con cáncer de vejiga no músculo-invasivo de alto riesgo y de riesgo intermedio, respectivamente
May 09, 2024 06:07 ET
|
Janssen Cilag International NV
Los resultados actualizados refuerzan el potencial de TAR-210 para transformar el tratamiento del cáncer de vejiga no músculo-invasivo con alteraciones del receptor del factor de crecimiento de...
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 01:00 ET
|
argenx SE
$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in...
Kratos Reports First Quarter 2024 Financial Results
May 07, 2024 16:00 ET
|
Kratos Defense & Security Solutions, Inc.
First Quarter 2024 Revenues of $277.2 Million Increased 19.6 Percent over First Quarter 2023 Revenues of $231.8 Million, including 19.5 Percent Organic Growth First Quarter 2024 Unmanned Systems...
Fortinet Threat Research Finds Cybercriminals Are Exploiting New Industry Vulnerabilities 43% Faster than 1H 2023
May 06, 2024 09:00 ET
|
Fortinet, Inc.
SUNNYVALE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- RSA Conference 2024 Derek Manky, Chief Security Strategist and Global VP Threat Intelligence, FortiGuard Labs“The 2H 2023 Global Threat Landscape...
Niemann-Pick Disease Type C Market Insight, Epidemiology and Market Forecast - 2032, Featuring Zevra Therapeutics, Azafaros, Cyclo Therapeutics and IntraBio
May 06, 2024 04:08 ET
|
Research and Markets
Dublin, May 06, 2024 (GLOBE NEWSWIRE) -- The "Niemann-Pick Disease Type C - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. ...
TAR-210 results show 90 percent recurrence-free survival and 90 percent complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively
May 05, 2024 14:39 ET
|
Janssen Cilag International NV
Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterations1 BEERSE, BELGIUM, May 05,...
Asia-Pacific Immersive Reality for Defense Industry Research Report 2024: Advancements Toward Next-Generation Command and Control (C2) System Platforms - Opportunity Forecasts to 2033
April 30, 2024 08:45 ET
|
Research and Markets
Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Asia-Pacific Immersive Reality for Defense Market: Focus on Type, Application, and Country - Analysis and Forecast, 2023-2033" report has been added...